Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

NCT ID: NCT02465515

Last Updated: 2019-03-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

9463 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-01

Study Completion Date

2018-03-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Albiglutide

Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.

Group Type EXPERIMENTAL

Albiglutide 30 mg

Intervention Type BIOLOGICAL

Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

Albiglutide 50 mg

Intervention Type BIOLOGICAL

Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

Placebo

Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.

Group Type PLACEBO_COMPARATOR

Albiglutide matching placebo

Intervention Type BIOLOGICAL

Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Albiglutide 30 mg

Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

Intervention Type BIOLOGICAL

Albiglutide 50 mg

Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.

Intervention Type BIOLOGICAL

Albiglutide matching placebo

Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women at least 40 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
* Diagnosis of type 2 diabetes.
* Established cardiovascular disease with at least one of the following: coronary artery disease, cerebrovascular disease, or peripheral arterial disease.
* HbA1c \>7.0% (53 mmol/mol) (based on the most recent documented laboratory measurement within 6 months).
* Able and willing to provide informed consent.

Exclusion Criteria

* Severely reduced kidney function: eGFR \<30 ml/min/1.73 m\^2 (based on the last measured and documented laboratory measurement within 6 months) or renal replacement therapy.
* Use of a GLP-1 receptor agonist at Screening.
* Severe gastroparesis
* History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study.
* Personal or family history of medullary carcinoma of the thyroid or subject with multiple endocrine neoplasia type 2 (MEN-2). Personal history of pancreatic neuroendocrine tumours.
* Medical history which might limit the subject's ability to take trial treatments for the duration of the study or to otherwise complete the study.
* Breastfeeding, pregnancy, or planning a pregnancy during the course of the study. Note: a pregnancy test will be performed on all women of child bearing potential prior to study entry.
* Known allergy to any GLP-1 receptor agonist or excipients of albiglutide.
* Use of another investigational product within 30 days or according to local regulations, or currently enrolled in a study of an investigational device.
* Any other reason the investigator deems the subject to be unsuitable for the study.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Duke Clinical Research Institute

OTHER

Sponsor Role collaborator

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Birmingham, Alabama, United States

Site Status

GSK Investigational Site

Birmingham, Alabama, United States

Site Status

GSK Investigational Site

Mobile, Alabama, United States

Site Status

GSK Investigational Site

Chandler, Arizona, United States

Site Status

GSK Investigational Site

Glendale, Arizona, United States

Site Status

GSK Investigational Site

Goodyear, Arizona, United States

Site Status

GSK Investigational Site

Tempe, Arizona, United States

Site Status

GSK Investigational Site

Tucson, Arizona, United States

Site Status

GSK Investigational Site

Tucson, Arizona, United States

Site Status

GSK Investigational Site

Little Rock, Arkansas, United States

Site Status

GSK Investigational Site

Searcy, Arkansas, United States

Site Status

GSK Investigational Site

Chula Vista, California, United States

Site Status

GSK Investigational Site

Lancaster, California, United States

Site Status

GSK Investigational Site

Lomita, California, United States

Site Status

GSK Investigational Site

Long Beach, California, United States

Site Status

GSK Investigational Site

Long Beach, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Moreno Valley, California, United States

Site Status

GSK Investigational Site

Northridge, California, United States

Site Status

GSK Investigational Site

Oakland, California, United States

Site Status

GSK Investigational Site

San Diego, California, United States

Site Status

GSK Investigational Site

San Diego, California, United States

Site Status

GSK Investigational Site

San Marino, California, United States

Site Status

GSK Investigational Site

San Ramon, California, United States

Site Status

GSK Investigational Site

Simi Valley, California, United States

Site Status

GSK Investigational Site

Stanford, California, United States

Site Status

GSK Investigational Site

Torrance, California, United States

Site Status

GSK Investigational Site

Denver, Colorado, United States

Site Status

GSK Investigational Site

Littleton, Colorado, United States

Site Status

GSK Investigational Site

Littleton, Colorado, United States

Site Status

GSK Investigational Site

New Haven, Connecticut, United States

Site Status

GSK Investigational Site

Belle Glade, Florida, United States

Site Status

GSK Investigational Site

Bradenton, Florida, United States

Site Status

GSK Investigational Site

Bradenton, Florida, United States

Site Status

GSK Investigational Site

Coral Gables, Florida, United States

Site Status

GSK Investigational Site

Coral Springs, Florida, United States

Site Status

GSK Investigational Site

Fleming Island, Florida, United States

Site Status

GSK Investigational Site

Inverness, Florida, United States

Site Status

GSK Investigational Site

Jacksonville, Florida, United States

Site Status

GSK Investigational Site

Lake Worth, Florida, United States

Site Status

GSK Investigational Site

Lakeland, Florida, United States

Site Status

GSK Investigational Site

Miami, Florida, United States

Site Status

GSK Investigational Site

Ocala, Florida, United States

Site Status

GSK Investigational Site

Ponte Vedra, Florida, United States

Site Status

GSK Investigational Site

Port Charlotte, Florida, United States

Site Status

GSK Investigational Site

Port Orange, Florida, United States

Site Status

GSK Investigational Site

St. Petersburg, Florida, United States

Site Status

GSK Investigational Site

Vero Beach, Florida, United States

Site Status

GSK Investigational Site

Wellington, Florida, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Conyers, Georgia, United States

Site Status

GSK Investigational Site

Cumming, Georgia, United States

Site Status

GSK Investigational Site

Decatur, Georgia, United States

Site Status

GSK Investigational Site

Dunwoody, Georgia, United States

Site Status

GSK Investigational Site

Snellville, Georgia, United States

Site Status

GSK Investigational Site

Tucker, Georgia, United States

Site Status

GSK Investigational Site

Aurora, Illinois, United States

Site Status

GSK Investigational Site

Champaign, Illinois, United States

Site Status

GSK Investigational Site

Gurnee, Illinois, United States

Site Status

GSK Investigational Site

Moline, Illinois, United States

Site Status

GSK Investigational Site

Avon, Indiana, United States

Site Status

GSK Investigational Site

Franklin, Indiana, United States

Site Status

GSK Investigational Site

Greenfield, Indiana, United States

Site Status

GSK Investigational Site

Muncie, Indiana, United States

Site Status

GSK Investigational Site

Munster, Indiana, United States

Site Status

GSK Investigational Site

West Des Moines, Iowa, United States

Site Status

GSK Investigational Site

Topeka, Kansas, United States

Site Status

GSK Investigational Site

Lexington, Kentucky, United States

Site Status

GSK Investigational Site

Louisville, Kentucky, United States

Site Status

GSK Investigational Site

New Orleans, Louisiana, United States

Site Status

GSK Investigational Site

Lewiston, Maine, United States

Site Status

GSK Investigational Site

Annapolis, Maryland, United States

Site Status

GSK Investigational Site

Saint Cloud, Minnesota, United States

Site Status

GSK Investigational Site

Saint Paul, Minnesota, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

Omaha, Nebraska, United States

Site Status

GSK Investigational Site

Las Vegas, Nevada, United States

Site Status

GSK Investigational Site

Camden, New Jersey, United States

Site Status

GSK Investigational Site

Haddon Heights, New Jersey, United States

Site Status

GSK Investigational Site

Albuquerque, New Mexico, United States

Site Status

GSK Investigational Site

Brooklyn, New York, United States

Site Status

GSK Investigational Site

North Massapequa, New York, United States

Site Status

GSK Investigational Site

Charlotte, North Carolina, United States

Site Status

GSK Investigational Site

Charlotte, North Carolina, United States

Site Status

GSK Investigational Site

Charlotte, North Carolina, United States

Site Status

GSK Investigational Site

Hickory, North Carolina, United States

Site Status

GSK Investigational Site

Rocky Mount, North Carolina, United States

Site Status

GSK Investigational Site

Salisbury, North Carolina, United States

Site Status

GSK Investigational Site

Statesville, North Carolina, United States

Site Status

GSK Investigational Site

Wilmington, North Carolina, United States

Site Status

GSK Investigational Site

Winston-Salem, North Carolina, United States

Site Status

GSK Investigational Site

Fargo, North Dakota, United States

Site Status

GSK Investigational Site

Cleveland, Ohio, United States

Site Status

GSK Investigational Site

Columbus, Ohio, United States

Site Status

GSK Investigational Site

Sandusky, Ohio, United States

Site Status

GSK Investigational Site

Springfield, Ohio, United States

Site Status

GSK Investigational Site

Toledo, Ohio, United States

Site Status

GSK Investigational Site

Camp Hill, Pennsylvania, United States

Site Status

GSK Investigational Site

Feasterville, Pennsylvania, United States

Site Status

GSK Investigational Site

Harleysville, Pennsylvania, United States

Site Status

GSK Investigational Site

Jersey Shore, Pennsylvania, United States

Site Status

GSK Investigational Site

Lansdale, Pennsylvania, United States

Site Status

GSK Investigational Site

Newport, Pennsylvania, United States

Site Status

GSK Investigational Site

Penndel, Pennsylvania, United States

Site Status

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

GSK Investigational Site

Sellersville, Pennsylvania, United States

Site Status

GSK Investigational Site

Pawtucket, Rhode Island, United States

Site Status

GSK Investigational Site

Anderson, South Carolina, United States

Site Status

GSK Investigational Site

Columbia, South Carolina, United States

Site Status

GSK Investigational Site

Myrtle Beach, South Carolina, United States

Site Status

GSK Investigational Site

Rapid City, South Dakota, United States

Site Status

GSK Investigational Site

Rapid City, South Dakota, United States

Site Status

GSK Investigational Site

Bristol, Tennessee, United States

Site Status

GSK Investigational Site

Kingsport, Tennessee, United States

Site Status

GSK Investigational Site

Memphis, Tennessee, United States

Site Status

GSK Investigational Site

Memphis, Tennessee, United States

Site Status

GSK Investigational Site

Nashville, Tennessee, United States

Site Status

GSK Investigational Site

Nashville, Tennessee, United States

Site Status

GSK Investigational Site

Arlington, Texas, United States

Site Status

GSK Investigational Site

Austin, Texas, United States

Site Status

GSK Investigational Site

Bellaire, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

El Paso, Texas, United States

Site Status

GSK Investigational Site

Georgetown, Texas, United States

Site Status

GSK Investigational Site

Houston, Texas, United States

Site Status

GSK Investigational Site

Huntsville, Texas, United States

Site Status

GSK Investigational Site

Kingwood, Texas, United States

Site Status

GSK Investigational Site

Plano, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

Schertz, Texas, United States

Site Status

GSK Investigational Site

Suite 101, Texas, United States

Site Status

GSK Investigational Site

Tyler, Texas, United States

Site Status

GSK Investigational Site

Layton, Utah, United States

Site Status

GSK Investigational Site

Manassas, Virginia, United States

Site Status

GSK Investigational Site

Federal Way, Washington, United States

Site Status

GSK Investigational Site

Spokane, Washington, United States

Site Status

GSK Investigational Site

Tacoma, Washington, United States

Site Status

GSK Investigational Site

Wenatchee, Washington, United States

Site Status

GSK Investigational Site

Madison, Wisconsin, United States

Site Status

GSK Investigational Site

Adrogué, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Bahía Blanca, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Mar del Plata, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Mar del Plata, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Pergamino, Buenos Aires, Argentina

Site Status

GSK Investigational Site

Córdoba, Córdoba Province, Argentina

Site Status

GSK Investigational Site

Godoy Cruz, Mendoza Province, Argentina

Site Status

GSK Investigational Site

San Rafael, Mendoza Province, Argentina

Site Status

GSK Investigational Site

Rosario, Santa Fe Province, Argentina

Site Status

GSK Investigational Site

Rosario, Santa Fe Province, Argentina

Site Status

GSK Investigational Site

Berazategui, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Buenos Aires, , Argentina

Site Status

GSK Investigational Site

Córdoba, , Argentina

Site Status

GSK Investigational Site

La Plata, , Argentina

Site Status

GSK Investigational Site

Mendoza, , Argentina

Site Status

GSK Investigational Site

Mendoza, , Argentina

Site Status

GSK Investigational Site

Mendoza, , Argentina

Site Status

GSK Investigational Site

Santa Fe, , Argentina

Site Status

GSK Investigational Site

Bonheiden, , Belgium

Site Status

GSK Investigational Site

Brussels, , Belgium

Site Status

GSK Investigational Site

Brussels, , Belgium

Site Status

GSK Investigational Site

Edegem, , Belgium

Site Status

GSK Investigational Site

Leuven, , Belgium

Site Status

GSK Investigational Site

Liège, , Belgium

Site Status

GSK Investigational Site

Roeselare, , Belgium

Site Status

GSK Investigational Site

Byala, , Bulgaria

Site Status

GSK Investigational Site

Gabrovo, , Bulgaria

Site Status

GSK Investigational Site

Montana, , Bulgaria

Site Status

GSK Investigational Site

Sevlievo, , Bulgaria

Site Status

GSK Investigational Site

Sofia, , Bulgaria

Site Status

GSK Investigational Site

Sofia, , Bulgaria

Site Status

GSK Investigational Site

Sofia, , Bulgaria

Site Status

GSK Investigational Site

Stara Zagora, , Bulgaria

Site Status

GSK Investigational Site

Kelowna, British Columbia, Canada

Site Status

GSK Investigational Site

Surrey, British Columbia, Canada

Site Status

GSK Investigational Site

Victoria, British Columbia, Canada

Site Status

GSK Investigational Site

Victoria, British Columbia, Canada

Site Status

GSK Investigational Site

Winnipeg, Manitoba, Canada

Site Status

GSK Investigational Site

Moncton, New Brunswick, Canada

Site Status

GSK Investigational Site

St. John's, Newfoundland and Labrador, Canada

Site Status

GSK Investigational Site

Halifax, Nova Scotia, Canada

Site Status

GSK Investigational Site

Truro, Nova Scotia, Canada

Site Status

GSK Investigational Site

Brampton, Ontario, Canada

Site Status

GSK Investigational Site

Burlington, Ontario, Canada

Site Status

GSK Investigational Site

Cambridge, Ontario, Canada

Site Status

GSK Investigational Site

Cornwall, Ontario, Canada

Site Status

GSK Investigational Site

Corunna, Ontario, Canada

Site Status

GSK Investigational Site

Greater Sudbury, Ontario, Canada

Site Status

GSK Investigational Site

Hamilton, Ontario, Canada

Site Status

GSK Investigational Site

London, Ontario, Canada

Site Status

GSK Investigational Site

London, Ontario, Canada

Site Status

GSK Investigational Site

Sarnia, Ontario, Canada

Site Status

GSK Investigational Site

Smiths Falls, Ontario, Canada

Site Status

GSK Investigational Site

Toronto, Ontario, Canada

Site Status

GSK Investigational Site

Brossard, Quebec, Canada

Site Status

GSK Investigational Site

Chicoutimi, Quebec, Canada

Site Status

GSK Investigational Site

Greenfield Park, Quebec, Canada

Site Status

GSK Investigational Site

Greenfield Park, Quebec, Canada

Site Status

GSK Investigational Site

Laval, Quebec, Canada

Site Status

GSK Investigational Site

Lévis, Quebec, Canada

Site Status

GSK Investigational Site

Montreal, Quebec, Canada

Site Status

GSK Investigational Site

Saint-Charles-Borromée, Quebec, Canada

Site Status

GSK Investigational Site

Saint-Lambert, Quebec, Canada

Site Status

GSK Investigational Site

Sherbrooke, Quebec, Canada

Site Status

GSK Investigational Site

Trois-Rivières, Quebec, Canada

Site Status

GSK Investigational Site

Beroun, , Czechia

Site Status

GSK Investigational Site

Krnov, , Czechia

Site Status

GSK Investigational Site

Olomouc, , Czechia

Site Status

GSK Investigational Site

Ostrava, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Příbram, , Czechia

Site Status

GSK Investigational Site

Uherské Hradiště, , Czechia

Site Status

GSK Investigational Site

Ústí nad Labem, , Czechia

Site Status

GSK Investigational Site

Zlín, , Czechia

Site Status

GSK Investigational Site

Copenhagen, , Denmark

Site Status

GSK Investigational Site

Esbjerg, , Denmark

Site Status

GSK Investigational Site

Frederikssund, , Denmark

Site Status

GSK Investigational Site

Hellerup, , Denmark

Site Status

GSK Investigational Site

Herlev, , Denmark

Site Status

GSK Investigational Site

Holbæk, , Denmark

Site Status

GSK Investigational Site

Hvidovre, , Denmark

Site Status

GSK Investigational Site

København NV, , Denmark

Site Status

GSK Investigational Site

København S, , Denmark

Site Status

GSK Investigational Site

Roskilde, , Denmark

Site Status

GSK Investigational Site

Amiens, , France

Site Status

GSK Investigational Site

Broglie, , France

Site Status

GSK Investigational Site

Corbeil-Essonnes, , France

Site Status

GSK Investigational Site

La Rochelle, , France

Site Status

GSK Investigational Site

Nantes, , France

Site Status

GSK Investigational Site

Narbonne, , France

Site Status

GSK Investigational Site

Paris, , France

Site Status

GSK Investigational Site

Pau, , France

Site Status

GSK Investigational Site

Pierre-Bénite, , France

Site Status

GSK Investigational Site

Strasbourg, , France

Site Status

GSK Investigational Site

Vandœuvre-lès-Nancy, , France

Site Status

GSK Investigational Site

Deggingen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Güglingen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Karlsruhe, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Ludwigsburg, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Stuttgart, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Stuttgart, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Villingen-Schwenningen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Wangen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Aschaffenburg, Bavaria, Germany

Site Status

GSK Investigational Site

Dachau, Bavaria, Germany

Site Status

GSK Investigational Site

Haag, Bavaria, Germany

Site Status

GSK Investigational Site

Künzing, Bavaria, Germany

Site Status

GSK Investigational Site

Rednitzhembach, Bavaria, Germany

Site Status

GSK Investigational Site

Wallerfing, Bavaria, Germany

Site Status

GSK Investigational Site

Elsterwerda, Brandenburg, Germany

Site Status

GSK Investigational Site

Falkensee, Brandenburg, Germany

Site Status

GSK Investigational Site

Potsdam, Brandenburg, Germany

Site Status

GSK Investigational Site

Flörsheim, Hesse, Germany

Site Status

GSK Investigational Site

Gelnhausen, Hesse, Germany

Site Status

GSK Investigational Site

Hildesheim, Lower Saxony, Germany

Site Status

GSK Investigational Site

Stuhr, Lower Saxony, Germany

Site Status

GSK Investigational Site

Wardenburg, Lower Saxony, Germany

Site Status

GSK Investigational Site

Bad Oeynhausen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bochum, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bochum, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Cologne, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Essen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Essen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Essen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Kleve, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Münster, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Witten, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bad Kreuznach, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Ludwigshafen am Rhein, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Mainz, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Sankt Ingbert, Saarland, Germany

Site Status

GSK Investigational Site

Chemnitz, Saxony, Germany

Site Status

GSK Investigational Site

Delitzsch, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Leipzg, Saxony, Germany

Site Status

GSK Investigational Site

Leipzig, Saxony, Germany

Site Status

GSK Investigational Site

Leipzig, Saxony, Germany

Site Status

GSK Investigational Site

Oschatz, Saxony, Germany

Site Status

GSK Investigational Site

Pirna, Saxony, Germany

Site Status

GSK Investigational Site

Riesa, Saxony, Germany

Site Status

GSK Investigational Site

Schkeuditz, Saxony, Germany

Site Status

GSK Investigational Site

Hohenmölsen, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Jerichow, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Magdeburg, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Dortmund, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Mannheim, , Germany

Site Status

GSK Investigational Site

München, , Germany

Site Status

GSK Investigational Site

Alexandroupoli, , Greece

Site Status

GSK Investigational Site

Athens, , Greece

Site Status

GSK Investigational Site

Athens, , Greece

Site Status

GSK Investigational Site

Athens, , Greece

Site Status

GSK Investigational Site

Haidari, Athens, , Greece

Site Status

GSK Investigational Site

Heraklion, Crete, , Greece

Site Status

GSK Investigational Site

Ioannina, , Greece

Site Status

GSK Investigational Site

Lamia, , Greece

Site Status

GSK Investigational Site

Nikaia Piraeus, , Greece

Site Status

GSK Investigational Site

Piraeus, , Greece

Site Status

GSK Investigational Site

Thessaloniki, , Greece

Site Status

GSK Investigational Site

Thessaloniki, , Greece

Site Status

GSK Investigational Site

Thessaloniki, , Greece

Site Status

GSK Investigational Site

Thessaloniki, , Greece

Site Status

GSK Investigational Site

Thessaloniki, , Greece

Site Status

GSK Investigational Site

Thessaloniki, , Greece

Site Status

GSK Investigational Site

Hong Kong, , Hong Kong

Site Status

GSK Investigational Site

Shatin, , Hong Kong

Site Status

GSK Investigational Site

Baja, , Hungary

Site Status

GSK Investigational Site

Budapest, , Hungary

Site Status

GSK Investigational Site

Budapest, , Hungary

Site Status

GSK Investigational Site

Debrecen, , Hungary

Site Status

GSK Investigational Site

Debrecen, , Hungary

Site Status

GSK Investigational Site

Eger, , Hungary

Site Status

GSK Investigational Site

Gödöllő, , Hungary

Site Status

GSK Investigational Site

Hatvan, , Hungary

Site Status

GSK Investigational Site

Komárom, , Hungary

Site Status

GSK Investigational Site

Miskolc, , Hungary

Site Status

GSK Investigational Site

Sátoraljaújhely, , Hungary

Site Status

GSK Investigational Site

Chieti, Abruzzo, Italy

Site Status

GSK Investigational Site

Bari, Apulia, Italy

Site Status

GSK Investigational Site

San Giovanni Rotondo (FG), Apulia, Italy

Site Status

GSK Investigational Site

Catanzaro, Calabria, Italy

Site Status

GSK Investigational Site

Napoli, Campania, Italy

Site Status

GSK Investigational Site

Napoli, Campania, Italy

Site Status

GSK Investigational Site

Bologna, Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Parma, Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Ravenna, Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Rome, Lazio, Italy

Site Status

GSK Investigational Site

Rome, Lazio, Italy

Site Status

GSK Investigational Site

Rome, Lazio, Italy

Site Status

GSK Investigational Site

Arenzano (GE), Liguria, Italy

Site Status

GSK Investigational Site

Bergamo, Lombardy, Italy

Site Status

GSK Investigational Site

Milan, Lombardy, Italy

Site Status

GSK Investigational Site

Milan, Lombardy, Italy

Site Status

GSK Investigational Site

Milan, Lombardy, Italy

Site Status

GSK Investigational Site

Vigevano (PV), Lombardy, Italy

Site Status

GSK Investigational Site

Olbia (OT), Sardinia, Italy

Site Status

GSK Investigational Site

Ancona, The Marches, Italy

Site Status

GSK Investigational Site

Ascoli Piceno, The Marches, Italy

Site Status

GSK Investigational Site

Siena, Tuscany, Italy

Site Status

GSK Investigational Site

S.Andrea Delle Fratte - S. Sisto (PG), Umbria, Italy

Site Status

GSK Investigational Site

Padua, Veneto, Italy

Site Status

GSK Investigational Site

Aguascalientes, Ags, Aguascalientes, Mexico

Site Status

GSK Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

GSK Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

GSK Investigational Site

Guadalajara, Jalisco, Mexico

Site Status

GSK Investigational Site

Tlaquepaque, Jalisco, Mexico

Site Status

GSK Investigational Site

Monterrey, Nuevo León, Mexico

Site Status

GSK Investigational Site

Monterrey NL, Nuevo León, Mexico

Site Status

GSK Investigational Site

Querétaro City, Querétaro, Mexico

Site Status

GSK Investigational Site

Mazatlán, Sinaloa, Mexico

Site Status

GSK Investigational Site

Mazatlán, Sinaloa, Mexico

Site Status

GSK Investigational Site

Mérida, Yucatán, Mexico

Site Status

GSK Investigational Site

Aguascalientes, , Mexico

Site Status

GSK Investigational Site

Mexico City, , Mexico

Site Status

GSK Investigational Site

Alkmaar, , Netherlands

Site Status

GSK Investigational Site

Amsterdam, , Netherlands

Site Status

GSK Investigational Site

Eindhoven, , Netherlands

Site Status

GSK Investigational Site

Gouda, , Netherlands

Site Status

GSK Investigational Site

Hardenberg, , Netherlands

Site Status

GSK Investigational Site

Heerlen, , Netherlands

Site Status

GSK Investigational Site

Hoogeveen, , Netherlands

Site Status

GSK Investigational Site

Meppel, , Netherlands

Site Status

GSK Investigational Site

Rotterdam, , Netherlands

Site Status

GSK Investigational Site

Sneek, , Netherlands

Site Status

GSK Investigational Site

Hoenefoss, , Norway

Site Status

GSK Investigational Site

Kolbjørnsvik, , Norway

Site Status

GSK Investigational Site

Oslo, , Norway

Site Status

GSK Investigational Site

Oslo, , Norway

Site Status

GSK Investigational Site

Stavanger, , Norway

Site Status

GSK Investigational Site

Trujillo, La Libertad, Peru

Site Status

GSK Investigational Site

San Martín de Porres, Lima region, Peru

Site Status

GSK Investigational Site

Callao, Lima, Peru

Site Status

GSK Investigational Site

Arequipa, , Peru

Site Status

GSK Investigational Site

Lima, , Peru

Site Status

GSK Investigational Site

Lima, , Peru

Site Status

GSK Investigational Site

Lima, , Peru

Site Status

GSK Investigational Site

Lima, , Peru

Site Status

GSK Investigational Site

Lima, , Peru

Site Status

GSK Investigational Site

Piura, , Peru

Site Status

GSK Investigational Site

Cebu City, , Philippines

Site Status

GSK Investigational Site

Iloilo City, , Philippines

Site Status

GSK Investigational Site

Laoag, , Philippines

Site Status

GSK Investigational Site

Bialystok, , Poland

Site Status

GSK Investigational Site

Bydgoszcz, , Poland

Site Status

GSK Investigational Site

Bydgoszcz, , Poland

Site Status

GSK Investigational Site

Gdansk, , Poland

Site Status

GSK Investigational Site

Gniewkowo, , Poland

Site Status

GSK Investigational Site

Katowice, , Poland

Site Status

GSK Investigational Site

Katowice, , Poland

Site Status

GSK Investigational Site

Krakow, , Poland

Site Status

GSK Investigational Site

Krakow, , Poland

Site Status

GSK Investigational Site

Krakow, , Poland

Site Status

GSK Investigational Site

Lublin, , Poland

Site Status

GSK Investigational Site

Poznan, , Poland

Site Status

GSK Investigational Site

Poznan, , Poland

Site Status

GSK Investigational Site

Sopot, , Poland

Site Status

GSK Investigational Site

Warsaw, , Poland

Site Status

GSK Investigational Site

Wierzchosławice, , Poland

Site Status

GSK Investigational Site

Wroclaw, , Poland

Site Status

GSK Investigational Site

Wroclaw, , Poland

Site Status

GSK Investigational Site

Wroclaw, , Poland

Site Status

GSK Investigational Site

Arkhangelsk, , Russia

Site Status

GSK Investigational Site

Barnaul, , Russia

Site Status

GSK Investigational Site

Chelyabinsk, , Russia

Site Status

GSK Investigational Site

Chelyabinsk, , Russia

Site Status

GSK Investigational Site

Ivanovo, , Russia

Site Status

GSK Investigational Site

Kemerovo, , Russia

Site Status

GSK Investigational Site

Kemerovo, , Russia

Site Status

GSK Investigational Site

Krasnodar, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Nizhny Novgorod, , Russia

Site Status

GSK Investigational Site

Nizhny Novgorod, , Russia

Site Status

GSK Investigational Site

Novosibirsk, , Russia

Site Status

GSK Investigational Site

Novosibirsk, , Russia

Site Status

GSK Investigational Site

Perm, , Russia

Site Status

GSK Investigational Site

Rostov-on-Don, , Russia

Site Status

GSK Investigational Site

Ryazan, , Russia

Site Status

GSK Investigational Site

Saint Petersburg, , Russia

Site Status

GSK Investigational Site

Samara, , Russia

Site Status

GSK Investigational Site

Saratov, , Russia

Site Status

GSK Investigational Site

Tomsk, , Russia

Site Status

GSK Investigational Site

Tomsk, , Russia

Site Status

GSK Investigational Site

Tomsk, , Russia

Site Status

GSK Investigational Site

Voronezh, , Russia

Site Status

GSK Investigational Site

Yaroslavl, , Russia

Site Status

GSK Investigational Site

Yaroslavl, , Russia

Site Status

GSK Investigational Site

Yaroslavl, , Russia

Site Status

GSK Investigational Site

Yaroslavl, , Russia

Site Status

GSK Investigational Site

Yekaterinburg, , Russia

Site Status

GSK Investigational Site

Yekaterinburg, , Russia

Site Status

GSK Investigational Site

Bloemfontein, Free State, South Africa

Site Status

GSK Investigational Site

Tongaat, KwaZulu-Natal, South Africa

Site Status

GSK Investigational Site

Bloemfontein, , South Africa

Site Status

GSK Investigational Site

Cape Town, , South Africa

Site Status

GSK Investigational Site

Houghton Estate, , South Africa

Site Status

GSK Investigational Site

Kuilsrivier, , South Africa

Site Status

GSK Investigational Site

Paarl, , South Africa

Site Status

GSK Investigational Site

Pinelands, , South Africa

Site Status

GSK Investigational Site

Umhlanga, , South Africa

Site Status

GSK Investigational Site

Daegu, , South Korea

Site Status

GSK Investigational Site

Daegu, , South Korea

Site Status

GSK Investigational Site

Gyeonggi-do, , South Korea

Site Status

GSK Investigational Site

Gyeonggido, , South Korea

Site Status

GSK Investigational Site

Kangwondo, , South Korea

Site Status

GSK Investigational Site

Pusan, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

Suwon, , South Korea

Site Status

GSK Investigational Site

Suwon, Kyonggi-do, , South Korea

Site Status

GSK Investigational Site

A Coruña, , Spain

Site Status

GSK Investigational Site

Alicante, , Spain

Site Status

GSK Investigational Site

Almería, , Spain

Site Status

GSK Investigational Site

Alzira/Valencia, , Spain

Site Status

GSK Investigational Site

Badalona, , Spain

Site Status

GSK Investigational Site

Badalona / Barcelona, , Spain

Site Status

GSK Investigational Site

Barcelona, , Spain

Site Status

GSK Investigational Site

Barcelona, , Spain

Site Status

GSK Investigational Site

Barcelona, , Spain

Site Status

GSK Investigational Site

Barcelona, , Spain

Site Status

GSK Investigational Site

Boadilla Del Monte (Madrid), , Spain

Site Status

GSK Investigational Site

Canet de Mar - Barcelona, , Spain

Site Status

GSK Investigational Site

Cangas Del Narcea/Asturias, , Spain

Site Status

GSK Investigational Site

Centelles (Barcelona), , Spain

Site Status

GSK Investigational Site

Córdoba, , Spain

Site Status

GSK Investigational Site

Elche, , Spain

Site Status

GSK Investigational Site

Granada, , Spain

Site Status

GSK Investigational Site

León, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Málaga, , Spain

Site Status

GSK Investigational Site

Palma de Mallorca, , Spain

Site Status

GSK Investigational Site

Palma de Mallorca, , Spain

Site Status

GSK Investigational Site

Pontevedra, , Spain

Site Status

GSK Investigational Site

Pozuelo de Alarcón/Madrid, , Spain

Site Status

GSK Investigational Site

Sagunto/Valencia, , Spain

Site Status

GSK Investigational Site

San Juan (Alicante), , Spain

Site Status

GSK Investigational Site

Sanlucar de Barrameda - Cádiz, , Spain

Site Status

GSK Investigational Site

Santa Coloma de Gramanet (Barcelona), , Spain

Site Status

GSK Investigational Site

Santiago de Compostela, , Spain

Site Status

GSK Investigational Site

Seville, , Spain

Site Status

GSK Investigational Site

Tarrasa, Barcelona, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Vigo-Pontevedra, , Spain

Site Status

GSK Investigational Site

Borås, , Sweden

Site Status

GSK Investigational Site

Eksjö, , Sweden

Site Status

GSK Investigational Site

Gothenburg, , Sweden

Site Status

GSK Investigational Site

Härnösand, , Sweden

Site Status

GSK Investigational Site

Helsingborg, , Sweden

Site Status

GSK Investigational Site

Karlskrona, , Sweden

Site Status

GSK Investigational Site

Kristianstad, , Sweden

Site Status

GSK Investigational Site

Linköping, , Sweden

Site Status

GSK Investigational Site

Ljungby, , Sweden

Site Status

GSK Investigational Site

Malmo, , Sweden

Site Status

GSK Investigational Site

Örebro, , Sweden

Site Status

GSK Investigational Site

Rättvik, , Sweden

Site Status

GSK Investigational Site

Stockholm, , Sweden

Site Status

GSK Investigational Site

Stockholm, , Sweden

Site Status

GSK Investigational Site

Stockholm, , Sweden

Site Status

GSK Investigational Site

Umeå, , Sweden

Site Status

GSK Investigational Site

Uppsala, , Sweden

Site Status

GSK Investigational Site

Changhua, , Taiwan

Site Status

GSK Investigational Site

Hualien City, , Taiwan

Site Status

GSK Investigational Site

Kaohsiung City, , Taiwan

Site Status

GSK Investigational Site

Taichung, , Taiwan

Site Status

GSK Investigational Site

Tainan City, , Taiwan

Site Status

GSK Investigational Site

Taipei, , Taiwan

Site Status

GSK Investigational Site

Taipei, , Taiwan

Site Status

GSK Investigational Site

Bangkok, , Thailand

Site Status

GSK Investigational Site

Bangkok, , Thailand

Site Status

GSK Investigational Site

Chiang Mai, , Thailand

Site Status

GSK Investigational Site

Pathum Thani, , Thailand

Site Status

GSK Investigational Site

Songkhla, , Thailand

Site Status

GSK Investigational Site

Chernivtsi, , Ukraine

Site Status

GSK Investigational Site

Dnipropetrovsk, , Ukraine

Site Status

GSK Investigational Site

Kharkiv, , Ukraine

Site Status

GSK Investigational Site

Kharkiv, , Ukraine

Site Status

GSK Investigational Site

Kherson, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Mykolaiv, , Ukraine

Site Status

GSK Investigational Site

Odesa, , Ukraine

Site Status

GSK Investigational Site

Poltava, , Ukraine

Site Status

GSK Investigational Site

Uzhhorod, , Ukraine

Site Status

GSK Investigational Site

Vinnytsia, , Ukraine

Site Status

GSK Investigational Site

Zaporizhzhya, , Ukraine

Site Status

GSK Investigational Site

Soham, Cambridgeshire, United Kingdom

Site Status

GSK Investigational Site

Chesterfield, Derbyshire, United Kingdom

Site Status

GSK Investigational Site

Romford, Essex, United Kingdom

Site Status

GSK Investigational Site

Northwood, Middlesex, United Kingdom

Site Status

GSK Investigational Site

Edinburgh, Midlothian, United Kingdom

Site Status

GSK Investigational Site

Trowbridge, Wiltshire, United Kingdom

Site Status

GSK Investigational Site

Aberdeen, , United Kingdom

Site Status

GSK Investigational Site

Axbridge, Somerset, , United Kingdom

Site Status

GSK Investigational Site

Ayr, , United Kingdom

Site Status

GSK Investigational Site

Blackpool, , United Kingdom

Site Status

GSK Investigational Site

Bristol, , United Kingdom

Site Status

GSK Investigational Site

Dumfries, , United Kingdom

Site Status

GSK Investigational Site

Dundee, , United Kingdom

Site Status

GSK Investigational Site

Dundee, , United Kingdom

Site Status

GSK Investigational Site

Dundee, , United Kingdom

Site Status

GSK Investigational Site

Fife, , United Kingdom

Site Status

GSK Investigational Site

Fife, , United Kingdom

Site Status

GSK Investigational Site

Gloucester, , United Kingdom

Site Status

GSK Investigational Site

Lancaster, , United Kingdom

Site Status

GSK Investigational Site

Manchester, , United Kingdom

Site Status

GSK Investigational Site

Newport, , United Kingdom

Site Status

GSK Investigational Site

Oxford, , United Kingdom

Site Status

GSK Investigational Site

Rotherham, , United Kingdom

Site Status

GSK Investigational Site

Sidcup, Kent, , United Kingdom

Site Status

GSK Investigational Site

Trowbridge, , United Kingdom

Site Status

GSK Investigational Site

Wigan, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Bulgaria Canada Czechia Denmark France Germany Greece Hong Kong Hungary Italy Mexico Netherlands Norway Peru Philippines Poland Russia South Africa South Korea Spain Sweden Taiwan Thailand Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

John McMurray, Stefano Del Prato, Adrian Hernandez, Larry Leiter, Chris Granger, Ralph D'Agostino, Jennifer Green, Kristina Sigmon, Anne Rosenberg Nigel Jones, Karl Thorpe, Matt Somerville, Salim Janmohamed. Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease. Lancet. 2018

Reference Type BACKGROUND

Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

Reference Type DERIVED
PMID: 39963952 (View on PubMed)

Gilbert MP, Skelly J, Hernandez AF, Green JB, Krychtiuk KA, Granger CB, Leiter LA, McMurray JJV, Del Prato S, Pratley RE. Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes Obes Metab. 2024 May;26(5):1714-1722. doi: 10.1111/dom.15479. Epub 2024 Feb 6.

Reference Type DERIVED
PMID: 38317618 (View on PubMed)

O'Brien EC, Raman SR, Ellis A, Hammill BG, Berdan LG, Rorick T, Janmohamed S, Lampron Z, Hernandez AF, Curtis LH. The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. Trials. 2021 Jul 19;22(1):465. doi: 10.1186/s13063-021-05397-0.

Reference Type DERIVED
PMID: 34281607 (View on PubMed)

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

Reference Type DERIVED
PMID: 30291013 (View on PubMed)

Green JB, Hernandez AF, D'Agostino RB, Granger CB, Janmohamed S, Jones NP, Leiter LA, Noronha D, Russell R, Sigmon K, Del Prato S, McMurray JJV. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. Am Heart J. 2018 Sep;203:30-38. doi: 10.1016/j.ahj.2018.03.030. Epub 2018 Jun 12.

Reference Type DERIVED
PMID: 30015066 (View on PubMed)

Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.

Reference Type DERIVED
PMID: 29693361 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-001824-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

116174

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.